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ABSTRACT  
Introduction: Most women who acquire HIV and other sexually transmitted infections (STIs) are in their child bearing years 
and are current or potential users of contraceptive methods. The study was undertaken to provide information on the 
association between the hormonal contraceptive methods and vulvo vaginal candidiasis among women attending Family 
Planning clinics, University College Hospital, Ibadan, Nigeria.  
Methods: It was a cross-sectional study in a population of women using hormonal contraceptive methods attending Family 
Planning clinics. Detailed medical history, endocervical and high vaginal swabs were collected from the women to establish 
diagnosis after clinical examination and informed consent. Aliquots of sera from venous blood samples of the women were 
tested for antibodies to HIV-1/2. Data was analysed using SPSS for windows’ version 17.0.  
Results: There were 116 women using hormonal contraceptive methods who participated in the study with mean age of 28.70 
years (SD = 6.72, range = 19 –54). The mean age of sexual debut of the women was 19.2 years (SD = 2.96). The prevalence of 
vulvo-vaginal candidosis was 23.3%. Other associated sexually transmitted infections were bacterial vaginosis (24.1%), HIV 
(12.1%), trichomoniasis (10.3%), chlamydia cervicitis (7.8%), syphilis (5.2%), genital warts (6.0%) and gonorrhoea (2.6%).Younger 
age of sexual debut influenced the decision of selecting various forms of hormonal contraceptives especially the emergence of 
oral contraceptive forms (P = 0.043). Majority of the women on hormonal contraceptives had multiple sexual partners. 
Vulvovaginal candidosis is strongly associated with vaginal discharge and pruritus in women utilizing hormonal contraceptive 
methods (P = 0.001, 4.2 (1.0–13.2). 
Conclusions: Women seeking contraception to prevent unintended pregnancy are as much in need of education about 
prevention of STIs. The study found that younger age, numbers sexual partners, and use of hormonal contraceptives could 
increase the risk of acquiring vulvovaginal candidosis.  
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ABSTRAIT 
Introduction: La plupart des femmes qui contractent le VIH et d'autres infections sexuellement transmissibles (IST) sont en âge 
de procréer et sont des utilisatrices actuelles ou potentielles de méthodes contraceptives. L'étude a été entreprise pour fournir 
des informations sur l'association entre les méthodes contraceptives hormonales et la candidose vulvo vagin chez les femmes 
fréquentant les cliniques de planification familiale, University College Hospital, Ibadan, Nigeria. 
Méthodes: Il s'agissait d'une étude transversale menée auprès d'une population de femmes utilisant des méthodes 
contraceptives hormonales dans des cliniques de planification familiale.  
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Des antécédents médicaux détaillés, des prélèvements endocervicaux et des prélèvements vaginaux élevés ont été effectués 
auprès des femmes pour établir un diagnostic après un examen clinique et un consentement éclairé. Des aliquotes de sérums 
d'échantillons de sang veineux des femmes ont été testées pour rechercher des anticorps anti-VIH-1/2. Les données ont été 
analysées à l'aide de SPSS pour la version 17.0 des veuves. 
Résultats: 116 femmes utilisant des méthodes contraceptives hormonales ont participé à l'étude avec un âge moyen de 28,70 ans 
(ET = 6,72, intervalle = 19-54). L'âge moyen des débuts sexuels des femmes était de 19,2 ans (ET = 2,96). La prévalence de la 
candidose vulvo-vaginale était de 23,3%. Les autres infections sexuellement transmissibles étaient la vaginose bactérienne 
(24,1%), le VIH (12,1%), la trichomonase (10,3%), la chlamydia cervicite (7,8%), la syphilis (5,2%), les verrues génitales et la 
gonorrhée. . L'âge plus jeune des débuts sexuels a influencé la décision de choisir différentes formes de contraceptifs 
hormonaux, en particulier l'émergence de formes contraceptives orales (p = 0,043). La majorité des femmes sur les contraceptifs 
hormonaux avaient plusieurs partenaires sexuels. La candidose vulvovaginale est fortement associée aux pertes vaginales et au 
prurit chez les femmes utilisant des méthodes contraceptives hormonales (p = 0,001, 4,2 (1,0-13,2). 
Conclusions: Les femmes qui recherchent une contraception pour prévenir les grossesses non désirées ont autant besoin 
d'éducation sur la prévention des IST. L'étude a révélé que le plus jeune âge, le nombre de partenaires sexuels et l'utilisation de 
contraceptifs hormonaux pourraient augmenter le risque d'acquisition de la candidose vulvo-vaginale. 
 
INTRODUCTION 
Contraception has been recognized as an important part 
of national efforts in many countries of the world to 
reduce adolescent pregnancies (1). Avoidance of 
unintended pregnancies requires access to,  and 
appropriate use of effective and safe methods of fertility 
control (2), This invariably leads to the improvement of 
reproductive health of sexually active young women (2). 
Unhindered access to effective and safe contraceptive 
methods could be the key to individual and public health 
safety.(3) A number of safe and effective contraceptive 
methods are available, and these include abstinence, 
barrier methods, oral contraceptives, Depo-Provera, 
Norplant implant, Intra-uterine devices, and sterilization 
methods (1).  
The current or potential users of different methods of 
contraceptives who acquire sexually transmitted 
infections and Human Immunodeficiency virus infections 
are in their child bearing years. There is a controversy 
over the extent to which specific contraceptive methods 
increase or perhaps reduce the risk of HIV infection(4). 
Hormonal contraception has been proven as one of the 
biological factors being linked to the acquisition of 
Human Immunodeficiency Virus (HIV) and other 
sexually transmitted infections (STIs).(5, 6) In a study 
conducted among a cohort of female sex workers in 
Kenya, compared with those who don’t practice 
contraception; those who rely on oral contraceptives 
(OCPs) are more likely to acquire chlamydia infection or 
vaginal candidiasis, but are less likely to acquire bacterial 
vaginosis. (6, 7) The assumptions are that the cervical 
ectopy produced by oral contraceptives (OCPs) results in 
affected cervical -zone being more vulnerable to trauma 
and thus perhaps to HIV infection.(8). Injectable 
hormonal contraceptives may increase the risk by 
increasing bleedings and thinning of the vaginal 
epithelium.(4) Most hormonal contraceptives contain 
either or both progesterone and oestrogen.(9)  
 
 
Hormonal contraceptives usually include combination of 
estrogen and progestin; and progestin only. Estrogen 
effects include inhibition of ovulation and prevention of 
follicular maturation through suppression of ovarian 
steroid production and possibly decreased 
responsiveness to gonadotropin-releasing hormone (9). 
Conversely, progestin leads to changes in the 
endometrium that make implantation less likely, 
increased thickness of cervical mucus that makes sperm 
penetration difficult, and impairment of normal tubal 
mobility.(10)  
In spite of recent therapeutic advances, vulvovaginal 
candidiasis remains a common global problem of public 
health importance.(11) The prevalence of vulvo-vaginal 
candidiasis varies worldwide, and in community- based 
survey conducted among female commercial sex workers 
in Ibadan, Nigeria, VVC was the commonest sexually 
transmitted infections reported (12) in women. It has 
been estimated that more than 70% of women develop at 
least one episode in their life time, (11) 50% experience a 
second episode, (11, 13, 14) while 5-8% encounter 
recurrences.(15) Oestrogen dominance usually enhances 
overgrowth of Candida spp in the vaginal milieu; and it 
has also been established in previous studies that oral 
contraceptives may determine the possibility of recurrent 
vulvo-vaginal candidiasis (14, 16, 17). Other predisposing 
factors linked to vaginal candidiasis include HIV 
infection, pregnancy, diabetes and undue prolonged use 
of antibiotics. (14, 18) Sexual behaviour could play an 
important role in the acquisition of VVC since some of 
the risk factors have been linked to the level of sexual 
activities with these women. Sexual behaviour has been 
linked to influence both primary VVC infections and 
relapses.(19) 
Presently there is a dearth of information of the 
prevalence of vulvo-vaginal candidiasis and its 
associated risk behaviours among hormonal 
contraceptive users in south western Nigeria. This study 
was aimed at evaluating the pattern of vulvo-vaginal 
candidiasis among the cohorts of hormonal contraceptive 
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users attending the family planning clinic, University 
College Hospital, Ibadan. 
 
MATERIALS AND METHODS 
This was a cross-sectional study carried out in a 
population of child-bearing age women using different 
types of hormonal contraceptive methods and attending 
family planning clinic, University College Hospital 
between March – December 2006.   
Sampling Procedure 
Women were recruited into the study as they presented 
to the clinic consecutively and freely gave informed 
consents. The women that were enrolled into the study 
completed structured questionnaires to obtain baseline 
information on their socio-demographic characteristics, 
reproductive health history including sexual behaviours; 
and different types of hormonal contraceptives being 
used.   Pre- test counselling was done for all clients 
recruited into the study which emphasized on client 
confidentiality; reasons for screening for candidiasis and 
HIV testing; information about their current and previous 
risk behaviours and also implication of positive test 
results. Women were excluded from being enrolled into 
the study if they were menstruating or have used 
antifungals especially the azoles in the preceding two 
weeks or within six weeks post-abortion. 
Physical Examination and Specimen Collection 
All women who freely gave informed consent and met 
the inclusion criteria had a complete pelvic examination 
under aseptic conditions for signs and symptoms 
suggestive of vulvovaginal candidiasis and other signs of 
sexually transmitted infections (STIs). High vaginal 
swabs and Endocervical swabs were collected from all 
the participants by the attending physicians following 
standard procedures. These samples were transported in 
Amies transport medium to the Special Treatment Clinic 
Laboratory, University College Hospital, Ibadan for 
microscopy, culture and sensitivity. The colour, character 
and the smell of the vaginal discharge were also noted.  
Laboratory Procedures 
Vaginal secretions collected were subjected to wet 
preparation and potassium hydroxide microscopy for the 
identification of round to oval budding yeast cells, 
trichomonads and clue cells. High vaginal secretions 
were also cultured on Sabouraud’s dextrose agar (SDA) 
at 37oC for 24 to 48hrs. Saline wet preparation of the 
creamy-greyish colonies revealed the presence of 
multiple budding yeast cells and pseudohyphae 
suggestive of Candida species. Species identification was 
confirmed based on the results obtained from germ tube 
tests, sugar assimilation and fermentation tests based on 
standard methods. Germ tubes positive isolates were 
confirmed as Candida albicans.   
Endocervical secretions were cultured for N. gonorrhoeae 
on modified Thayer Martins Agar. The media plates were 
incubated at 370C in 5% CO2 humidified extinction jar. 
Endocervical secretions were also Gram-stained for the 
presence of intracellular diplococci which were later 
confirmed as Neisseria gonorrhoeae by standard laboratory 
methods. Endocervical secretions were also tested for 
Chlamydia trachomatis by QuickView Chlamydia test kits 
following standard procedures (20). Diagnosis of genital 
warts was based on the clinical findings of typical lesions 
as previously described various researchers on the 
external genitalia, vaginal, cervix and perianal region. 
(21-23) 
HIV-serology testing was done by rapid 
immunochromatographic test strips using OraQuick 
ADVANCETM rapid HIV- 1 / 2 antibody testing. Any 
sample positive on screening was re-tested with enzyme-
linked immunosorbent assay (ELISA) and confirmed by 
western blot analysis. Approval for the study was 
obtained from UI/UCH ethics review committee.  
Data Analysis  
Data analysis was done using SPSS software, version 17.0 
(SPSS Inc., Chicago, IL, USA). Summary statistics such as 
proportions for categorical variables; means and standard 
deviation for continuous variables were estimated. The 
variables included for the analysis were women’s age, 
educational level, religion, ethnicity, marital status, 
occupation, age of sexual debut, numbers of sexual 
partners by the women, numbers of multiple partners of 
their spouses, types of contraceptives and prevalence of 
candidiasis.  Frequency distribution tables for each of the 
variables were analysed. Odds ratio and confidence 
interval were calculated to evaluate the association 
between sexual behaviour, hormonal contraception and 
prevalence of candidiasis. Multivariate analysis was used 
to assess the effect of the confounding variables. 
Statistical significance was set at P < 0.05. 
RESULTS                                                                                        
During the study period, a total of one hundred and 
sixteen women attending family planning clinic at the 
University College hospital; that fulfilled the inclusion 
criteria and using different hormonal contraceptives were 
included in the analysis. Table 1 shows the 
sociodemographic characteristics and the rate of 
candidiasis of the women. The mean age of the women 
was 28.70 years (SD = 6.72, range = 19 –54). Sixty-six (66, 
56.9%) were in the 20-29 age range and more than half (16 
of 27, 59.3%) of this age group were infected with 
candidiasis. Nearly half of them also (57, 49.1%) were 
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secondary school leavers and fifty of them (50, 43.1%) 
were neither married nor living with a partner. Table 1.  
The mean age of sexual debut of the women was 19.2 
years (SD = 2.96) Fifty-five of them had their sexual debut 
with their casual friends and school mates while only 30 
(25.9%) initiated sex with their spouses. (Table 2)  
 
TABLE 1: SOCIO-DEMOGRAPHIC CHARACTERISTICS OF THE PARTICIPANTS 
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Level of  
Education 
No formal education 
Primary school 
Secondary school 













Marital Status  Not married, Not living with a partner 
Not married, Living with a partner 
Married , Not living with a partner 






























Choice of hormonal contraceptives was statistically 
significant for younger women (Mean= 22.5 years). 
Younger age of sexual debut also influenced the 
choice of hormonal contraceptives especially the 
emergency contraceptives pills. Table 3 shows that 
thirty-six (31.0%) of the women preferred injectable 
hormonal contraceptives while thirty (25.9%) were 
taking oral contraceptives. Those women on oral 
contraceptive had the highest rate of VVC (11 of 27, 
40.1%). The odds of women on oral contraceptive 
having VVC are slightly higher but are not 
statistically significant. (Table 3)  
The prevalence of vulvo-vaginal candidosis in this 
study was 23.3% (27 of 116), Nineteen (70.4%) were C. 




TABLE 2: SEXUAL AND REPRODUCTIVE HISTORY OF THE WOMEN 
Variables Categories Frequency 
N=116 (%) 
Candidiasis n=27(%) P- value 
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TABLE 3:  TYPES OF HORMONAL CONTRACEPTIVES 





Oral Contraceptives 30 25.9 
















TABLE 4:                         TABLE 4: PATTERN OF VULVO-VAGINAL 
CANDIDIASIS AND OTHER STIS AMONG WOMEN 








Bacterial vaginosis 28 24.1 
Trichomoniasis 12 10.3 
Chlamydia trachomatis  9 7.8 
Gonorrhoea 3 2.6 
Genital warts 7 6.0 
HIV infection 14 12.1 
 
Other sexually transmitted infections diagnosed 
include bacterial vaginosis (24.1%), trichomoniasis 
(10.3%), Chlamydia trachomatis infection (7.8%), 
Gonorrhea (2.6%), genital warts (6.0%) and HIV 
infection (12.1%) as shown in Table 4. There was no 
significant association between the women infected 
with candidiasis and acquisition of HIV infection. 
Five (18.5%) of the women with vulvovaginal 
candidiasis were diagnosed with HIV infection. (P = 
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0.24). However, two (66.7%) of the patients with 
gonorrhoea were infected with HIV infection. 
Gonorrhoea was found to be significantly associated 
with HIV acquisition P = 0.003). The odds ratio of 
hormonal contraceptive users infected with 
gonorrhoea acquiring HIV infection was 16.8 (1.4-
199.8). Other STIs were not associated with 
acquisition of HIV. (Table 5) 
TABLE 5: ASSOCIATION OF VULVOVAGINAL CANDIDIASIS AND OTHER STIS WITH HIV INFECTION 







22 (81.5) 5 (18.5) 0.24 2.02 (0.61-6.6) 
Bacterial vaginosis 25 (89.3) 3 (10.7) 0.801 0.84(0.22-3.2) 
Trichomoniasis 9 (75.0) 3 (25.0) 0.146 2.82 (0.66-11.9) 
Chlamydia trachomatis  7(77.8) 2 (22.2) 0.330 2.2 (0.421-12.1) 
Gonorrhoea 1(33.3) 2 (66.7) 0.003* 16.8 (1.4-199.8) 
Genital warts 6 (85.7) 1 (14.3) 0.850 1.23 ( 0.137-11.05) 
 
TABLE 6: ASSOCIATION OF VULVO-VAGINAL CANDIDIASIS WITH HORMONAL CONTRACEPTIVES TYPE AND 
OTHER RISK FACTORS 
Infection Vulvo-vaginal candidiasis P Value OR (95% CI) 
Types of 
Contraceptives / 





Oral Contraceptives  8 (26.7) 22 (72.3) 0.610 0.78 (0.30-2.03) 
Injectable 
Contraceptives 
8 (22.2) 28 (77.8) 0.857 1.06(0.426-2.78) 
Norplant implant  0 (0.0) 2 (100.0) 0.432 2.82 (0.66-11.9) 
Emergency 
Contraceptives 
11 (22.9) 37 (77.1) 0.939 1.04 (0.43-2.46) 
Multiple sexual 
partners  
26 (42.6) 35 (57.4) 0.261 1.04 (0.96-1.12) 
Douching 7 (16.3) 36 (83.7) 0.171 1.94 (0.74-5.06) 
Vaginal discharge 23 (45.1) 28 (54.9%) 0.001 12.5 (3.9.-39.5) 
Vaginal pruritus 17 (53.1) 15 (46.9) 0.001 2.2 (1.4- 3.7) 
HIV Infection 5 (35.7) 9 (64.3) 0.24 2.02 (0.61-6.6) 
Trichomoniasis 3 (25.0) 9 (75.0%) 0.88 1.01(0.87-1.18) 
Bacterial vaginosis 10 (35.7) 18 (64.3) 0.56 2.3 (0.91-5.9) 
Chlamydia Cervicitis 3 (33.3) 6 (66.7) 0.46 1.7 (0.42-7.4) 
 
In this study, Eleven (40.7%) of the women infected 
with vulvovaginal candidiasis were regular 
emergency oral contraceptive users.  Acquisition of 
VVC was observed more in women who had multiple 
sexual partners in the preceding one month before the 
study, though not statistically significant (P = 0.068).  
96.3% (26 of 27) of women infected with VVC had 
multiple sexual partners. Douching was also found to 
increase the risk of acquisition of VVC. 25.9% of 
women with VVC usually practice douching (P= 
0.171). (Table 6) 
DISCUSSION  
Vulvovaginal candidiasis is a common gyneacological 
health problem that is usually diagnosed in women of 
child bearing age;(24) and it has been associated with  
profound morbidity in all strata of women all over 
44 
 
the world.(11)  In our study, the prevalence of 
vulvovaginal candidosis was 23.3% among women 
attending the family planning clinic in University 
College Hospital, Ibadan, Nigeria. This is the second 
most common infection after bacterial vaginosis 
(24.1%). The results of previous studies have 
confirmed similar rates that ranged from 18.5-30%. 
(25, 26) However, this rate is much lower than 84.5% 
discovered in Kano, Nigeria (27); 45.0% obtained by 
Namkinga et al in Dar es Salaam (28) and 40% found 
by Ibrahim and his colleagues in Maiduguri, Nigeria 
(29). This finding may not be unconnected with the 
fact that some of the women could have some 
underlying asymptomatic co-morbidity especially 
diabetes mellitus. The prevalence of yeast infections 
has also greatly increased worldwide because of 
indiscriminate use of antibiotics and 
immunosuppressive treatment.(30) Tarry et al have 
established that the use of oral contraceptives with 
high oestrogen content could encourage increased 
vaginal colonisation with Candida spp (31) 
In this study, we found out that more than half 
(56.9%) of those seeking contraceptive use are in their 
active reproductive age (20-29 years old) and only 
6.9% are in the 40-59 years age bracket. The mean age 
of women in this study is 28.7 years.  This result is not 
unexpected as most of these young women were 
single, sexually active and prefer hormonal 
contraceptives. The finding is in concordance with 
previous study by Fisher and Boroditsky that 
examined sexual activity of single Canadian women 
aged 15-29.(32). Vulvovaginal candidiasis (VVC) was 
more common in women aged 20-29 years (59.3%) 
and lowest in 40-59 years (7.4%). This finding was 
also in agreement with other study that showed that 
the incidence of vulvovaginal candidiasis usually 
peaks in the third decade of life and reduces in 
women older than 40 years of age.(19)  Despite the 
higher number of single women using hormonal 
contraceptives, prevalence of VVC was noticed more 
in married women living with their spouses. This 
might not be unconnected with increased sexual 
activities with married women. This finding agreed 
with Okungbowa et al who reported similar findings 
among married women.(19)  
Sexual risk behaviours that have been documented to 
influence the acquisition of VVC were not statistically 
significant in our study. Early age of sexual debut (16-
20 years) accounted for higher rate of VVC (16 of 27, 
70.4%) but is not significantly associated with the 
infection. Women that engage with at least two or 
more casual sex partners also had increased rate of 
VVC (13 of 27, 48.1%) with no significant association 
for the acquisition of VVC.  This was not in agreement 
with the findings of Hellberg et al and Rathod et al 
that reported age of sexual debut; casual sex partners 
and regular oral sex being associated with repeated 
VVC. (33, 34)  However, this is in agreement with the 
findings of Corsello et al  that believed that  increased 
number of sexual partners, age of sexual debut and 
increased frequency of sexual intercourse were not 
significantly risk factors associated with VVC.(35)   
Douching has been documented to be an important 
risk factor for the acquisition of vulvovaginal 
candidosis in previous studies (34, 36) .In our study, 
seven (25.9%) of the women who had VVC usually 
practice douching , however, this was not found to be 
statistically significant (p=0.171). Vaginal discharge 
was the commonest presentation (51 of 116, 44.0%) 
closely followed by vaginal pruritus (32 of 116, 
27.6%). Some of these women also presented with the 
combination of vaginal discharge and vulvo-vaginal 
pruritus at the time of study. Almost all women that 
presented with vaginal pruritus (31 of 32, 96.9%) also 
had vaginal discharge.  It was noticed that more than 
half of women (17 of 27, 53.1%) that presented with 
pruritus had VVC. Vaginal pruritus has been found to 
be significantly associated (p=0.001) with the 
occurrence of VVC in our study. These findings were 
in tandem with the results of similar studies that 
reported either combination of the symptoms or 
vaginal pruritus alone. (27, 37) (Table 6) 
Types of hormonal contraceptives could also 
influence the acquisition of VVC. In this study, it was 
found that usages of oral and emergency 
contraceptives were found to be the commonest; 
however none of the hormonal contraceptive methods 
in this study was significantly associated with the 
acquisition of VVC.  Eleven (22.9%) of the 48 women 
using emergency contraceptives had VVC and this is 
not statistically significant. This finding is similar to 
some studies that believed oral contraceptive alone 
may not influence the recurrence of VVC (16, 38). 
However, this is not in agreement with the findings of 
another study that found that users of oral 
contraceptive pills are at increased risk for acquisition 
of VVC.(6) 
Vulvo-vaginal candidiasis has been linked as risk 
factor for the increased acquisition of HIV in 
hormonal contraceptive users. However, in our study 
there was no significant association between VVC and 
acquisition of HIV (P=0.24), only five (18.5%) of those 
women infected with VVC were seropositive for HIV 
infection. Our finding is not in agreement with the 
study of Martins et al that found a strong trend of 
association between the use of high dose of oral 
contraceptive pills and HIV acquisition. (5)  The 
prevalence of Chlamydia cervicitis and gonococcal 
cervicitis in this study was 7.8% and 2.6% 
respectively. There was no significant association 
between the acquisitions of VVC and Chlamydial 
infection (P= 0. 46). This result was in tandem with 
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the previous studies regarding use of combined oral 
contraceptives and cervical Chlamydia infections (6, 
39, 40). However, few of these studies reported 
conflicting results. In a prospective cohort study in 
the U.S. it was found that women using COCs were 
not at increased risk of developing  gonorrheal or 
chlamydial cervical infection compared with women 
using non-hormonal contraception (39). Other 
infections like bacterial vaginosis, genital warts and 
trichomoniasis were not strongly associated with 
development of VVC in women using hormonal 
contraceptives in this study.  
Young age, education, Christianity, non-marital 
status, and lower social class; influenced the choice 
and use of different hormonal contraceptive method 
though no significant association. Hormonal 
contraceptives users were associated with increased 
prevalence of vulvovaginal candidiasis in this study 
though not statistically significant. Vaginal discharge 
and vulvovaginal pruritus are the commonest 
symptoms that are strongly associated with VVC. 
There is need for public health enlightment 
programme to educate women using hormonal 
contraceptives methods to adopt safer sexual 
behaviours, as well as seeking early diagnosis and 
treatment of VVC and other sexually transmitted 
infections. The main limitation in this study was the 
lack of speciation of the non-albicans strains of 
Candida and was due to unavailability of 
Chromogenic Agar (CHROM agar) and other 
molecular diagnostic facilities in our center then. 
Temporal causality could not be established since this 
is a cross sectional study. Our small size limitation 
could also have interfered with the ability to fully 
explore the various associations. 
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